mfap4 and treatment of fibrosis

Grith Lykke Sørensen* (Inventor), Anders Schlosser (Inventor), Uffe Holmskov (Inventor)

*Corresponding author for this work

Research output: Patent


The present invention relates to a selective targeting agent, which is capable of binding MFAP4 and inhibiting MFAP4-integrin interaction for use in the prevention, alleviation and/or treatment of fibrosis. The invention further comprises compositions comprising said selective targeting agents.
Original languageEnglish
Patent numberAU2022259467 (A1)
Priority date12/04/2021
Priority numberWO2022EP59600
Publication statusPublished - 5. Oct 2023


Dive into the research topics of 'mfap4 and treatment of fibrosis'. Together they form a unique fingerprint.

Cite this